United Statesstate reportOH

Psychedelic research and access in

Ohio

Federally, the baseline remains restrictive for classical psychedelics. In Ohio law, psilocybin and psilocin are treated as controlled substances under the state schedules, and Ohio has not verifiedly created a statewide regulated psilocybin or natural-medicine services pathway.

Key Insights

  • 1

    Ohio remains a prohibition state for classical-psychedelic access, even though ketamine stays available through ordinary controlled-medical channels.

  • 2

    The policy conversation has advanced to a formal Ibogaine Treatment Study Committee, which is more serious than informal debate but still short of legal access.

  • 3

    Official Ohio Board of Pharmacy material points to a non-trivial in-state psilocybin research footprint, including at least seven Ohio trials.

  • 4

    Ohio currently fits best as a “research and legislative study” state, not an implementation state.

Research Snapshot

Deep report

Blossom currently tracks 35 psychedelic clinical trials with verified sites in Ohio, including 13 active studies.

Active trials
13

Verified state-linked study sites

Total trials
35

Linked trial records

Stakeholders
12

12 physical, 0 jurisdiction-linked

Events
0

Linked state-level events

Top Compounds

  • Ketamine(13)
  • Esketamine(12)
  • Psilocybin(6)
  • LSD(4)

Top Study Topics

  • Major Depressive Disorder (MDD)(13)
  • Treatment-Resistant Depression (TRD)(13)
  • Anxiety Disorders(3)
  • Suicidality(3)
  • Depressive Disorders(2)

Active Trial Preview

View linked trials →

Access and Reimbursement

Ketamine/esketamine access; no state-regulated classical psychedelic pathway

For patients, the realistic lawful access picture is conventional. Ketamine may be delivered through ordinary medical practice where clinicians and facilities offer it, and esketamine remains an FDA-approved product administered through certified settings under REMS requirements. That is separate from psychedelic policy reform.

Research signal

Not Reviewed

Ohio appears stronger on research than on access. The clearest official signal is the Ohio Board of Pharmacy’s Apr 2026 material noting at least seven psilocybin trials in Ohio.

Ketamine / esketamine

Available

For patients, the realistic lawful access picture is conventional. Ketamine may be delivered through ordinary medical practice where clinicians and facilities offer it, and esketamine remains an FDA-approved product administered through certified settings under REMS requirements.

No state service model

Not Available

No state-regulated psilocybin, MDMA or natural-medicine service model is verified for Ohio.

Classical psychedelics

Not Available

The strongest verified current policy signal is the Ohio House Ibogaine Treatment Study Committee. The General Assembly’s calendar listed a committee meeting on 6 May 2026, showing that legislative interest has moved beyond abstract discussion into structured study activity.

Reimbursement / payment

Limited

Coverage appears plan-specific, with off-label ketamine generally facing more reimbursement friction than REMS-governed esketamine.

Policy and Access Timeline

State-level bills, laws, pilots, agency actions and reimbursement signals that shape real-world access.

  1. 18 May 2026

    ActiveAgency Guidance

    Ohio Administrative Code continued to list ketamine in Schedule III

    Ohio Administrative Code continued to list ketamine in Schedule III.

    Ohio
    Ohio Administrative Code rule 4729:9-1-03→

  2. 1 Apr 2026

    ActiveAgency Guidance

    Ohio Board of Pharmacy material said there were at least seven psilocybin trials in Ohio

    Ohio Board of Pharmacy material said there were at least seven psilocybin trials in Ohio.

    Ohio
    Ohio Board of Pharmacy rules and resolutions→

  3. 1 Oct 2018

    ActiveAgency Guidance

    Ohio’s Revised Code schedules continued to include psilocybin and psilocin in the state...

    Ohio’s Revised Code schedules continued to include psilocybin and psilocin in the state controlled-substance framework.

    Ohio
    Ohio Revised Code § 3719.41; Ohio Administrative Code rule 4729:9-1-01→

Regulatory Status

Federally, the baseline remains restrictive for classical psychedelics. In Ohio law, psilocybin and psilocin are treated as controlled substances under the state schedules, and Ohio has not verifiedly created a statewide regulated psilocybin or natural-medicine services pathway. Ketamine, by contrast, remains in Ohio Schedule III, which keeps it within ordinary medical controlled-substance practice rather than classical-psychedelic prohibition. That makes Ohio’s present position relatively clear: prohibition on classical-psychedelic access outside research, but ordinary lawful ketamine/esketamine care can exist through standard medical routes. Nothing in the reviewed Ohio materials supports describing the state as having a live psychedelic-services implementation model.

Medical Access Summary

For patients, the realistic lawful access picture is conventional. Ketamine may be delivered through ordinary medical practice where clinicians and facilities offer it, and esketamine remains an FDA-approved product administered through certified settings under REMS requirements. That is separate from psychedelic policy reform.###

This source pass did not verify any Ohio public programme that authorises psilocybin, MDMA, ibogaine, DMT or mescaline for routine patient access. The state is therefore best framed to distinguish sharply between research activity and actual access: Ohio may be research-active, but it is not yet a patient-access jurisdiction for classical psychedelics.###

Local Research Map

Verified Blossom records with coordinates in Ohio, including trial sites, physical stakeholders and events.

Policy and Access Context

The strongest verified current policy signal is the Ohio House Ibogaine Treatment Study Committee. The General Assembly’s calendar listed a committee meeting on 6 May 2026, showing that legislative interest has moved beyond abstract discussion into structured study activity.###

At the same time, Ohio has not enacted an Oregon-style access programme. Ohio Board of Pharmacy materials from Apr 2026 referred to more than 200 psilocybin trials overall, including at least seven in Ohio, which suggests that research pressure is building even though the state has not opened a general access route.###

Research Focus

Ohio appears stronger on research than on access. The clearest official signal is the Ohio Board of Pharmacy’s Apr 2026 material noting at least seven psilocybin trials in Ohio. That is important because it places Ohio in the “research state, not access state” category.###

Specific named Ohio trial sites require direct registry rechecking; Ohio has a meaningful trial footprint, but specific sponsoring institutions and current recruitment statuses should be manually rechecked on ClinicalTrials.gov before relying on current access details.###

Implementation Context

Ohio does not presently have verified implementation machinery for state-regulated psychedelic services. There is no reviewed evidence here of facilitator licensing, service-centre regulation, advisory-board rulemaking, mandatory client data collection, or product-testing rules aimed at psilocybin services.###

The implementation story is therefore still pre-regulatory. The ibogaine study committee is noteworthy, but a study committee is not a patient programme, and a research footprint is not a service network. That distinction will matter for journalists, investors, and patient-access researchers.###

Ecosystem Context

Ohio’s verified ecosystem currently looks legislative and research-oriented rather than service-oriented. The two strongest public markers are the House Ibogaine Treatment Study Committee and the Board of Pharmacy’s acknowledgement of multiple Ohio psilocybin trials.###

This source pass did not verify a current statewide ecosystem of regulated psychedelic clinics or a local decriminalisation map from primary Ohio sources in this source pass. The page should therefore avoid implying an access ecosystem that the law has not yet created.###

Key Milestones

Oct 2018
Ohio’s Revised Code schedules continued to include psilocybin and psilocin in the state controlled-substance framework.
6 May 2024 code version
Ohio Administrative Code continued to list ketamine in Schedule III.
Apr 2026
Ohio Board of Pharmacy material said there were at least seven psilocybin trials in Ohio.
6 May 2026
The House Ibogaine Treatment Study Committee appeared on the Ohio legislative calendar.

Future Outlook

In the next 12 to 24 months, Ohio is worth watching primarily for ibogaine and research-linked policy proposals rather than immediate psilocybin implementation. The House study committee could create a path to future legislation, especially if lawmakers keep the frame tightly focused on veterans, addiction, PTSD, or other high-visibility indications.###

Actual patient access is a different question. Unless the legislature moves from study to statute, Ohio will remain a conventional care state where ketamine/esketamine are the practical routes and classical psychedelics remain confined to research settings. Trial recruitment and any introduced follow-on bills should be checked again immediately before publishing.###

Sources and Verification

Last updated 18 May 2026. Source links are drawn from citation annotations in the subnational report.

  1. 1Ohio Administrative Code rule 4729:9-1-03
  2. 2Ohio Board of Pharmacy rules and resolutions
  3. 3Ohio Legislative Calendar
  4. 4Ohio Revised Code § 3719.41; Ohio Administrative Code rule 4729:9-1-01